Today, CLSA applauded the U.S. House passage of H.R. 184, the Protect Medical Innovation Act, which permanently repeals the job and innovation hindering 2.3% medical device excise tax levied on medical technology companies.
CLSA is proud that hundreds of our innovative member companies call the Bay Area home, and we look forward to working with Mayor-elect London Breed and her Administration to advance thoughtful policies that will grow and ensure the vibrancy of San Francisco’s treasured life sciences ecosystem.
2018 – 2019 state budget includes $30 million for Precision Medicine Research
Newly introduced legislation bridges Medicare patient access gaps and modernizes policies to allow coverage of medical technologies approved through FDA’s expedited review process
Report shows that the life science industry continues to be a strong job engine for California; over 85% of companies surveyed indicate plans to add technical employees in the next year, particularly in R&D, Quality and Regulatory Affairs/Compliance.
California Life Sciences Association (CLSA) today announced a new Chair and the addition of a new member to its Board of Directors. William J. Newell, Chief Executive Officer of Sutro Biopharma, Inc., transitioned from Vice Chair to Chair of the Board. Jared L. Watkin, Senior Vice President, Diabetes Care, Abbott, has joined the Board of Directors. In addition, Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS, formerly CLSA’s Treasurer, was appointed as the new Vice Chair of the organization.
Bipartisan Legislators Named 2018 Visionary Award Recipients for Promoting Policies that Advance Biomedical Innovation at CLSA’s Annual Washington, D.C. Program
CLSA, the trade association representing California’s life sciences sector, today announced the opening of an expanded office and events center in San Francisco, which is home to many of the top life sciences companies in the state.
CLSI today named Presentation High School Sophomore Shloka Janapaty of San Jose, CA as the winner of CLSI’s 2018 Amgen Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field.
OCTANe, Orange County’s life sciences and technology accelerator and California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today announced the Life Sciences Growth Accelerator Program – a unique dual membership program designed to address the specific growth challenges of emerging life sciences companies.
Legislators Honored with Award for Commitment to Strengthening California Life Sciences Sector at CLSA’s Back to Session Reception in Sacramento
CLSA, the trade association representing California’s life sciences industry, today commended the U.S. Senate’s confirmation of Alex Azar as the new secretary of the U.S. Department of Health and Human Services (HHS).
California Life Sciences Association (CLSA) applauds the House and Senate passage of legislation that temporarily suspends the ill-conceived 2.3% medical device tax for an additional 2 years, until December 2019.
CLSA today issued the following statement applauding Governor Jerry Brown’s 2018 – 2019 California budget proposal that calls for $30 million to be invested in precision medicine research and the establishment of the California Institute to Advance Precision Health and Medicine (CIAPHM).
California Life Sciences Association (CLSA) welcomes the introduction of H.R. 4617, legislation that places a 5-year freeze on the ill-conceived 2.3% medical device excise tax. Without swift enactment of this measure, the medical device tax would further hamper innovation and investment in medical technology research and development.
California Life Sciences Association (CLSA) and PwC US newly released annual California Life Sciences Industry Report, provides a snapshot of the largest life sciences cluster in the world. The 2018 report shows that California continues to outpace other states in life science-related economic growth, including venture funding, National Institutes of Health (NIH) funding, digital health venture funding, and is producing nearly 300,000 jobs and shepherding more than a thousand new therapies through the pipeline.
For over 7 years, CLSA has advocacted for repeal of IPAB because such blunt cost containment approaches could seriously harm the delicate cycle of biomedical innovation by reducing incentives for investment in new research and product development, and ultimately limit patient access to lifesaving treatments, therapies and technologies.
Esteemed Industry Leaders to be Honored for Contributions to California’s Thriving Life Sciences Sector on Nov. 10
California Life Sciences Association (CLSA), the statewide public policy and business leadership trade association representing California’s life sciences industry, today announced winners of the 2017 Pantheon DiNA Awards, a distinguished awards program honoring innovation and excellence within California’s life sciences sector.
Six Board Appointments Add Leadership from Bay City Capital, BD, Cal State Long Beach, Celgene, Genentech and USC
U.S. Senate Approves Measure to Support Operations at the FDA to Help Propel Bioscience & MedTech Investment and Innovation
Sponsored by CLSA, AB 602 Protects Patients with Diabetes from Counterfeit or Improperly Sold Diabetes Test Devices
California Life Sciences Association (CLSA) applauds Governor Jerry Brown, California State Senate and California Assembly leaders for their strong support of life sciences innovation, as demonstrated again in this year’s 2017-2018 budget deal which allocates a $10 million investment in precision medicine research.
California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, today issued the following statement in response to the President’s FY 2018 budget request.
WASHINGTON & BAY AREA, May 9, 2017 – California Life Sciences Association (CLSA), the state’s premier public policy and business solutions organization representing the California life sciences industry, today commended the U.S. Senate’s confirmation of Scott Gottlieb, M.D., as the new commissioner of the U.S. Food and Drug Administration (FDA). As the key federal agency … Continue reading CLSA Applauds Confirmation of Dr. Scott Gottlieb as New FDA Commissioner
California Life Sciences Association (CLSA) today announced an expansion of its board of directors, adding two new members. Wade Ackerman, Partner at Covington & Burling LLP and Richard Ascroft, Vice President, Managed Market and Government Affairs at Takeda Pharmaceuticals USA, Inc., have joined the CLSA board.
CLSA Appoints Jayne McNicol to be Organization’s New Chief Financial Officer and Lead Financial Functions
CLSA announces a major expansion to its advocacy team, hiring three new government relations directors based in its Sacramento and Washington, D.C. offices, bringing its in-house advocacy staff count to 9 personnel. Oliver Rocroi has been hired as Senior Director, State Government Relations; Manny Heer has been hired as Director, Alliance Development & Advocacy; and Adam Lotspike has been hired as Associate Director, Federal Government Relations.
CLSA President & CEO Sara Radcliffe comments on the President’s proposed $6 billion cut to the National Institutes of Health (NIH) in his budget blueprint.
Larry W. Kwak and Daria Mochly-Rosen elected to CLSA Board
Legislators Honored for Commitment to Strengthening and Promoting California Life Sciences Sector
San Diego Congressman Named to U.S. House Committee Critical to Continued Success of San Diego’s Life Sciences Community.
CLSA congratulates Congresswoman Mimi Walters on her appointment to the prestigious House Energy and Commerce Committee, which holds broad authority and jurisdiction over matters that are critical to the continued success of California’s life sciences sector.
The Protect Medical Innovation Act of 2017, introduced today in the U.S. House, would permanently eliminate 2.3% excise tax on medical device manufacturers.
CLSI announced today that it will celebrate the expansion of its FAST Accelerator program to Davis and Southern California – and its designation as the West Coast accelerator for combating antimicrobial resistance (CLSI CARB-X) – at a special FAST Showcase & Reception on Dec. 13 at the Wilsey Theater and Education Studio of the War Memorial Building in San Francisco.
CLSA-endorsed bipartisan package of innovative reforms will help propel U.S. life sciences research, investment and innovation
Bipartisan package of innovative reforms will help propel U.S. life sciences research, investment and innovation.
California Life Sciences Association (CLSA) invites media to attend the 2016 Pantheon DiNA Awards, a distinguished awards program honoring innovation and excellence within California’s life sciences sector. CLSA is California’s largest and most influential life sciences advocacy and business leadership organization representing California’s leading life sciences innovators.
California Life Sciences Association (CLSA) and PwC US issue new report indicating that California’s life sciences industry has 1,269 new medicines in the development pipeline, and in 2015, employed more than 287,000 people, brought in $148 billion in total revenue, paid over $116,000 in average wages, attracted $4.4 billion in venture capital investment and more.
For Immediate Release: Nov. 4, 2016 Community Leader Honored for Dedication to Life Sciences Education of Bay Area’s Youth at California Life Sciences Associations 2016 Pantheon DiNA Awards, Dec. 2. SAN FRANCISCO – (Nov. 3, 2016) – California Life Sciences Association (CLSA), the state’s largest and most influential life sciences advocacy and business leadership organization … Continue reading Elizabeth Schar to be Named Recipient of CLSA’s Biotechnology Educator Award for Outstanding Contributions to Ravenswood City School District
Senior Executives from Actelion Pharmaceuticals US, Alexandria Real Estate Equities, Johnson & Johnson Innovation, JLABS, Leerink Partners and Sanofi Genzyme Join CLSA Board of Directors
Esteemed Life Sciences Leaders Honored for Contributions to California’s Life Sciences Community
Esteemed Innovators to be Honored for California Life Sciences Contributions at 2016 Pantheon DiNA Award Program in San Francisco
CLSA applauds the congressional passage of the Advancing Hope Act, a bill to foster drug development for rare diseases in children.
California Life Sciences Association Partners with LA BioMed and Lab Launch to Grow World-Class Life Sciences Innovation Hub in Los Angeles; Opens Los Angeles Office
CLSA identifies several areas of concern and suggestions for improvement regarding the cost and value of new drugs and medical technologies.
California Life Sciences Institute (CLSI) today announced the appointment of Heather Shane to build and lead the CLSI CARB-X accelerator, which will provide non-dilutive funding, business support and subject matter expertise to companies with innovative antibiotic product candidates.
CLSA & OCTANe today announced a formal alliance to strategically accelerate the growth of Orange County’s life sciences sector.
California Life Sciences Association Announces Expansion of Board of Directors, with Senior executives from Allergan and Boehringer Ingelheim Fremont Inc. joining CLSA’s board.
On Thursday, July 28, the California Life Sciences Association (CLSA) will host its “Afternoon with Thought Leaders” program in La Jolla, Calif., and convene an important discussion on Pandemic Preparedness: The Public-Private Research and Response Infrastructure. Members of the media are invited to attend.
California Life Sciences Association (CLSA), the statewide public policy organization representing over 750 of California’s leading life sciences innovators, today issued the following statement regarding Senate Bill (SB) 1010, which passed by the California Assembly Health Committee yesterday. SB 1010 prioritizes paperwork, red tape and bureaucracy over research, and instead of improving patient access and affordability, places patients in California at risk. This statement can be attributed to Sara Radcliffe, President & CEO, California Life Sciences Association (CLSA).
California NAACP joins the California Chronic Care Coalition, California Senior Advocates League, Friedreich’s Ataxia Research Alliance (FARA), Council for Citizens Against Government Waste, TechNet, California Hepatitis C Task Force and others to voice concerns regarding SB 1010, a bill by State Sen. Ed Hernandez, which prioritizes paperwork, red tape and bureaucracy over research, and instead of improving patient access and affordability, places patients in California at risk.
California Life Sciences Association Expands Advocacy Team. Michael Bolden joins CLSA as Sacramento-Based Sr. Director of State Gov’t Relations. Jenny Carey, Reese Isbell and Will Zasadny promoted.
For Immediate Release: June 9, 2016 Report shows California’s life science industry is one of the leading employers in the state, creating jobs for over 280,000 people. SAN FRANCISCO – Biocom Institute and California Life Sciences Institute (CLSI) today released a joint life sciences industry workforce trends report entitled, “2016 Talent Integration: California Workforce Trends in … Continue reading Biocom Institute and California Life Sciences Institute Release 2016 California Life Sciences Sector Workforce Trends Report
From our non-profit partner, CLSI’s latest report demonstrates that Bay Area life science startups are making significant contributions to local and state economy with public and private funding, job creation, and innovative discoveries. Almost half of surveyed companies have a woman in the C-suite.
California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical.
AB 2115 would ensure patients losing health coverage are notified about prescription-drug discount plans
Patients and the life sciences community have partnered to protect access to new medicines and oppose SB 1010. The bill, by Sen. Ed Hernandez, prioritizes paperwork and bureaucracy over research, and instead of improving patient access and affordability, places patients in California at the end of the line.
Bridget Hood, a lupus patient and Lupus L.A. board member, pens an op-ed in the O.C. Register on the need to for policymakers to protect medical innovation, and not make any kind of policy decisions that would intentionally or unintentionally slow that progress down.
California Legislators Named 2016 Visionary Award Winners
SB 1010 would prioritize paperwork and bureaucracy over research and development, inhibit medical progress and, instead of improving patient access and affordability, place patients in California at the end of the line.
CLSA applauds the introduction of H.R. 5009, legislation that bridges Medicare patient access gaps and modernizes policies to allow coverage of technologies approved through FDA’s expedited review process.
CLSA’s own Eve Bukowski, our VP of State Government Relations and a cancer fighter pens a letter to the editor of CALMatters, which pushes back on a recent article in CALMatters (“California Searches for Prescription to Treat Rising Drug Costs,” April 10) that suggests the state simply could not afford to treat poor patients who need life-saving medicines to treat their serious or even life-threatening illness.
CLSA statement on SB 1010, problematic legislation that distorts the true cost landscape, could lead to shortages, conflicts with federal law, and ignores any benefits of the targeted medicines.
On April 13, California Life Sciences Association (CLSA), the statewide public policy organization representing over 750 of California’s leading life science innovators, applauded Assemblymember Jim Wood (D-Healdsburg) for introducing AB 2115, a measure which would help ensure patients in California receive important information about the availability of essential medicines.
California Life Sciences Institute (CLSI) names Cupertino High School Sophomore Utkarsh Tandon as the winner of the 2016 Amgen Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field.
CLSA & BCG release an infographic report, “Tracking FDA Drug Review Performance,” which shows that the FDA has accelerated review times, descending from an average of 21 months in 2009 to 10 months in 2015.
The California Life Sciences Institute is pleased to help host San Francisco’s 2016 STEM Career Awareness Day.
On Feb. 29 at the State Capitol, the California Life Sciences Association (CLSA) participated in an event recognizing Feb. 29 as Rare Disease Day in California as acknowledged in Senate Concurrent Resolution 108, authored by Senator Bill Monning (D – Carmel) and co-authored by Assemblymember Katcho Achadjian (R – San Luis Obispo).
California Life Sciences Association statement on the U.S. Senate confirmation of Dr. Robert Califf to be the next Commissioner of the U.S. Food and Drug Administration (FDA).
California Life Sciences Association (CLSA) welcomes to its board of directors two new members: Robert Ford, Executive Vice President, Medical Devices, Abbott and Mark Ginestro, Principal, Healthcare and Life Sciences, KPMG LLP.
Legislators Recognized for Strengthening and Promoting California’s Life Sciences Sector
CLSA Kick-Starts New Year with Hire of Kelly Bryant to oversee membership, strategic alliance, and membership value.
Statement from CLSA President & CEO Sara Radcliffe regarding Assembly Bill (AB) 463, the so-called Pharmaceutical Cost Transparency Act of 2016.
California Life Sciences Association (CLSA) applauds Governor Jerry Brown and his Administration for their unwavering support of life sciences innovation, as demonstrated again in this year’s budget which calls for a $10 million investment in precision medicine research.
CLSA statement on proposed delay of the 2.3% medical device tax as part of year-end tax agreement in Congress.
California Life Sciences Association (CLSA), today announced that its board of directors appointed three new members: William Annett, Chief Executive Officer, OncoCyte; Perry Nisen, M.D., Ph.D., Chief Executive Officer and Donald Bren Chief Executive Chair, Sanford Burnham Prebys Medical Discovery Institute; and James Sabry, M.D., Ph.D., Senior Vice President, Genentech Partnering.
CLSA & PwC’s 2016 Life Sciences Industry Report indicates that California’s life sciences sector has a profound impact on the state’s economy, showing industry increases in the areas of sector employment growth, wages, research funding and life sciences venture investment.
California Life Sciences Association (CLSA) to Recognize California’s Booming Life Sciences Industry and Leading Innovators Nov. 17 in San Francisco
Combined Entity to Continue Mission of Fueling the Entrepreneurship, Education and Career Development that Support the Bioeconomy
New California Life Sciences Association (CLSA) and Boston Consulting Group (BCG) report shows progress made, but room for improvement remains in FDA medical device review times.
According to CLSA & Biocom, Issa’s remarks dismissive of concerns of life sciences sector in San Diego and across California SOUTH SAN FRANCISCO & SAN DIEGO – Sept. 21, 2015 – California Life Sciences Association (CLSA) and Biocom delivered a letter to Rep. Darrell Issa (R-CA) expressing disappointment with recent remarks, reported in POLITICO, regarding … Continue reading CLSA & Biocom Respond to Rep. Darrell Issa on Patent Litigation Legislation Comments
Sara Radcliffe, President & CEO of CLSA, has been chosen to participate on 2015’s BIO Investor Forum Advisory Committee.
CLSA issues a statement on appointing three new leaders from City of Hope National Medical Center, Hogan Lovells US LLP and UC Davis to their board during the 3rd quarter meeting of 2015.
On July 10, the House overwhelmingly approved the 21st Cures Act, a comprehensive legislative package to accelerate the pace of biomedical research and development in the U.S. CLSA President & CEO Sara Radcliffe comments on the passage of this landmark legislation.
The repeal of the device tax will encourage investment, entrepreneurship and innovation in some of the world’s most vibrant medical technology clusters throughout California, from San Diego, Orange County and greater Los Angeles to Silicon Valley and the San Francisco Bay Area region.
CLSI launched today to focus on fostering the innovation that has made California home to the world’s most prominent life sciences ecosystem. The Institute was previously known as the BayBio Institute, which was established in 1990. Today, CLSI works to ensure that the economic and intellectual power of California’s life sciences sector and its employees remains strong.
California Life Sciences Association (CLSA) statement on House Judiciary Committee passage of H.R. 9, the so-called “Innovation” Act. Without substantial changes, the legislation jeopardizes America’s leadership in life sciences research, investment and innovation.
The 21st Century Cures Act is not only visionary, but critical to ensuring that California and our nation remains the worldwide leader in life sciences research, investment and innovation.
Todd Gillenwater is promoted to Executive Vice President – Advocacy & External Relations. Will lead CLSA’s federal, state and local government relations, policy, alliance development and communications activities
CLSA is now the largest state and regional life sciences advocacy group in the country, with more than 750 members.
Draft legislation boosts biomedical research funding, modernizes life sciences innovation ecosystem
AB 463 was not brought up for a vote in the California State Assembly Committee on Health. Bill exculsively targeted a sector providing life saving medicines, and failed to recognize the clinical and economic value to patients and the healthcare system provided by these life saving medications.
FOR IMMEDIATE RELEASE: April 21, 2015 California Healthcare Institute Statement on AB 463 So-called “Pharmaceutical Cost Transparency Act” would stifle innovation, exclusively targets a sector providing life saving medicines SAN DIEGO – April 21, 2015 – The California Healthcare Institute (CHI), a non-profit representing more than 275 leading life sciences organizations, released the following statement by … Continue reading California Healthcare Institute Statement on AB 463
FOR IMMEDIATE RELEASE: April 14, 2015 California’s Life Sciences Sector Applauds Gov. Brown on New Public-Private Precision Medicine Initiative California Initiative to Advance Precision Medicine will focus on data sharing between UC System and industry to advance precision therapies San Diego, Calif. – April 14, 2015 – Sara Radcliffe, president & CEO of the California … Continue reading California’s Life Sciences Sector Applauds Gov. Brown on New Public-Private Precision Medicine Initiative
FOR IMMEDIATE RELEASE: March 6, 2015 California’s Life Sciences Sector Hosts NIH Director in San Diego Biocom, California Healthcare Institute and UC San Diego host Dr. Francis Collins for Town Hall and Roundtable Discussion San Diego, Calif. – March 6, 2015 – Today, the California Healthcare Institute (CHI), Biocom and UC San Diego hosted Francis Collins, M.D., Ph.D., Director of the … Continue reading California’s Life Sciences Sector Hosts NIH Director in San Diego
FOR IMMEDIATE RELEASE: March 2, 2015 California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian CHI partners with Achadjian for resolution to promote awareness of more than 7,000 rare diseases SACRAMENTO – March 2, 2015 – Today at the State Capitol, Assemblymember Katcho Achadjian (R-San Luis Obispo), in partnership with the California Healthcare … Continue reading CHI Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian
FOR IMMEDIATE RELEASE: Feb. 25, 2015 California Healthcare Institute Applauds Efforts to Protect FDA Budget from Sequestration Reps. Eshoo and Lance lead efforts to protect FDA from cuts to industry-paid user fees LA JOLLA, Calif., Feb. 25, 2015 – CHI-California Healthcare Institute issued the following statement in support of the FDA SOS (Safety Over Sequestration) … Continue reading CHI Applauds Efforts to Protect FDA Budget from Sequestration
FOR IMMEDIATE RELEASE: Feb. 6, 2015 California Healthcare Institute, BayBio, Biocom and CONNECT Statement on Reintroduction of the Innovation Act La Jolla, San Diego & South San Francisco, Calif., Feb. 6, 2015 – CHI-California Healthcare Institute, BayBio, Biocom and CONNECT issued the following joint statement regarding the introduction of patent litigation reform legislation – H.R. … Continue reading California Healthcare Institute, BayBio, Biocom and CONNECT Statement on Reintroduction of the Innovation Act
CHI-California Healthcare Institute, BayBio, Biocom and CONNECT issued the following joint statement regarding the introduction of patent litigation reform legislation — H.R. 9, the Innovation Act — in the U.S. House of Representatives this week. This statement may be attributed to Sara Radcliffe, President & CEO, CHI; Gail Maderis, President & CEO, BayBio; Joe Panetta, President & CEO, Biocom; and Greg McKee, CEO, CONNECT.
CHI Statement on 21st Century Cures initiative discussion draft. The legislation calls for input to spur biomedical innovation through increased efficiency and patient perspectives
California Healthcare Institute (CHI) announced today the election of two senior leaders to serve on its board of directors: Stephanie Okey, head of North America, Rare Diseases and senior vice president, general manager U.S. Rare Diseases business for Genzyme, and Tony Semedo, senior vice president, Medtronic & president, Aortic & Peripheral Vascular.
Draft legislation boosts biomedical research funding, modernizes life sciences innovation ecosystem
CHI-California Healthcare Institute issued the following statement today in response to newly introduced bipartisan legislation authored by Reps. Erik Paulsen (R-Minn.) and Ron Kind (D-Wis.) to repeal the 2.3 percent medical device excise tax levied on medical device firms as part of the Affordable Care Act.
Draft legislation boosts biomedical research funding, modernizes life sciences innovation ecosystem
CHI and BayBio announced that the two organizations have signed a letter of intent to merge their operations into a newly created organization, to be called the California Life Sciences Association (CLSA), representing the entire biomedical ecosystem of the state of California in one organization. The merger of the two organizations is expected to be completed by end of the first quarter of 2015.
Nearly one in five new FDA approvals and more than one in four IPOs in 2014 came from Bay Area companies. BayBio will celebrate this record of success at its 11th annual BayBio Pantheon DiNA Awards ceremony on December 11, 2014.
California Healthcare Institute (CHI) announced today the election of two senior leaders to serve on its board of directors: Beth Roberts, partner, Hogan Lovells US LLP and George Savage, M.D., chief medical officer, Proteus Digital Health. CHI is a nonprofit, public policy research organization, representing leading California academic institutions, including biotechnology, medical device, diagnostics and pharmaceutical firms.
Today the National Institutes of Health (NIH) announced the initial round of grants for the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, an undertaking that aims to develop and revolutionize new methods of understanding the complexities and neuro circuit functions of the human brain. This first round of grants totaling $46 million in funding for fiscal year 2014 was allocated to more than 100 investigators in 15 states and several countries. California-based academic and private research institutions were awarded 20 of the total 58 grants, supported through this round of funding.
California’s life science cluster is a major economic engine for the state, creating $258 billion in economic activity and over one million jobs that pay $76 billion in salaries, wages and benefits and driving the need for integrated talent.
California’s life science cluster is a major economic engine for the state, creating $258 billion in economic activity and over one million jobs that pay $76 billion in salaries, wages and benefits and driving the need for integrated talent.
California Healthcare Institute (CHI) applauds Representative Kevin McCarthy (R-Bakersfield) on his election today, by his peers in the House Republican conference, as House Majority Leader— the second highest leadership position in the United States House of Representatives.
BayBio named Henry M. Gunn High School senior Emily Wang of Palo Alto as the winner of the 2014 Amgen Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. As the Amgen Bay Area BioGENEius finalist, Wang will gain insider access to the biotechnology industry by attending the 2014 BIO International Convention in San Diego, the industry’s trade conference, where leading companies, scientists and innovators will offer her invaluable advice and first-hand experience on the limitless possibilities within one of the world’s most innovative industries.
Today at the state Capitol, Assemblymember Kevin Mullin (D-South San Francisco), in partnership with the California Healthcare Institute (CHI), presented House Resolution 32 recognizing Feb. 28 as Rare Disease Day in California. CHI is a nonprofit, public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
Governor Jerry Brown delivered his annual State of the State address in Sacramento and included top mention of the biomedical community in the state. CHI-California Healthcare Institute has worked closely with the Governor and his Office of Business and Economic Development (GO-Biz) to prioritize the needs of the ever-expanding life sciences ecosystem in California.
Boehringer Ingelheim Fremont, Inc. will receive the 2013 BayBio Pantheon DiNA Global Reach Award at the 10th Annual BayBio Pantheon Ceremony on December 5th.
California Healthcare Institute (CHI) is celebrating its 20th anniversary at its Annual Meeting at Genentech. Industry thought leaders will participate on panels discussing FDA regulatory policies, nurturing innovation in the face of sequestration and lack of venture capital (VC) investment, as well as highlight the patient experience. CHI and PwC will also release its annual 2014 California Biomedical Industry Report with enhanced new data on employment, revenue, VC funding and impact in the state.
SOUTH SAN FRANCISCO, Calif. – November 11, 2013 – COMETRIQ¬Æ (cabozantinib) by Exelixis, Inc. will receive the 2013 BayBio Pantheon DiNA for Outstanding Product Award (Therapeutic) at the 10th Annual BayBio Pantheon Ceremony on December 5. COMETRIQ was nominated for its activity in progressive, metastatic medullary thyroid cancer, a disease state for which, until recently, there … Continue reading Exelixis, Inc. to Receive BayBio Award at 10th Annual Pantheon Ceremony
SOUTH SAN FRANCISCO, Calif. – Nov. 7, 2013 – Congresswoman Jackie Speier will receive the 2013 BayBio Pantheon DiNA for Public Support Award at the 10th Annual BayBio Pantheon Ceremony on December 5th. Congresswoman Speier worked with the industry for years as a San Mateo County Supervisor, Assembly Member, State Senator, and now as a … Continue reading Congresswoman Jackie Speier to Receive BayBio Award at 10th Annual Pantheon Ceremony
BayBio supports new legislation introduced by Senators Robert Menendez (D-NJ) and Pat Toomey (R-PA) that is designed to increase capital formation for R&D-focused companies in the early stages of development.
Myelin Repair Foundation President and CEO Scott Johnson will receive the 2013 BayBio Pantheon DiNA Biotechnology Philanthropist Award at the 10th Annual BayBio Pantheon Ceremony on December 5th.
Supporters of SB 598 are reacting with disappointment over California Gov. Jerry Brown’s veto Saturday of legislation that would have made the necessary updates to state regulations in anticipation of FDA-approved biosimilar medicines. SB 598 (Hill — San Mateo) received overwhelming bipartisan approval throughout the legislative process, passing 176-13 in five committees and three floor votes in the Assembly and Senate and was supported by hundreds of patient advocate, physician, healthcare, biotech, labor and business groups.
SOUTH SAN FRANCISCO, CA – Oct. 3, 2013 – A prolific investor, responsible for dozens of successful life science companies, and a professor, whose seminal work helped launch the biotechnology industry as we know it, are among the luminaries being celebrated at this year’s 10th annual BayBio Pantheon DiNA Awards ceremony. Sam Colella, a partner … Continue reading BayBio Announces the 10th Annual Pantheon Award Winners
A new collaboration between BayBio and QB3, two of the Bay Area’s leading entrepreneur-supporting organizations, will expand the service offerings available to Northern California life science startup companies.
SB 598 Awaits Governor’s Signature SACRAMENTO, Calif. – Sept. 4, 2013 – A bill updating California’s pharmacy substitution law to allow greater patient access to more affordable FDA-approved biologic medicines is headed to the Governor’s desk after today’s overwhelming passage in the Senate in a 30 to 2 vote. Senate Bill 598, authored by Sen. … Continue reading Biosimilars Bill Secures Final Approval in California State Legislature
New Advisory Program Connects Startups to Strength and Experience of the World’s Leading Life Science Cluster SOUTH SAN FRANCISCO, Calif. – July 17, 2013 – A new BayBio program aims to help the most promising young Bay Area life science companies fast-track their way to funding and success by drawing on the vast and rich … Continue reading BayBio Launches Program to Fast Track Startup Funding and Success
On the heels of strong bi-partisan support in the Senate, SB 598, authored by Sen. Jerry Hill (D-San Mateo), was approved today by the Assembly Business and Professions Committee on a 12-0 vote. The bill now moves to the Assembly Health Committee.
CHI-California Healthcare Institute today submitted a letter to House Appropriators and the California congressional delegation, joined by over 40 biomedical companies, urging them to restore sequestered industry user fees paid to the U.S. Food and Drug Administration in 2013, and to ensure that future across-the-board cuts will not include user fees paid to FDA, as part of the FY14 Agriculture, Rural Development and FDA Appropriations Bill. CHI is a non-profit public policy research and advocacy organization for California’s biomedical R&D industry.
Today, legislation to regulate the dispensing of biosimilars, known as SB 598 and authored by Sen. Jerry Hill (D-San Mateo), passed the California State Senate overwhelmingly, with 29 voting in favor, four voting against and six abstaining. As the statewide public policy association representing California’s innovative life sciences sector including biotechnology, pharmaceutical, medical device and diagnostics companies, venture capital firms, research universities and institutes and its 275,000 workers, CHI strongly supports this legislation and applauds Sen. Hill for his leadership and efforts in championing the passage of SB 598.
CHICAGO, ILL. – April 23, 2013 – Monta Vista High School junior Natalie Ng was declared the winner of the 2013 International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng secured the victory at the 2013 BIO International Convention in Chicago, the industry’s trade conference. Two other … Continue reading Cupertino Student Wins International Science Competition
SOUTH SAN FRANCISCO, Calif. – April 22, 2013 – – The Coalition of State Bioscience Institutes (CSBI) and Booz & Company have issued a report, entitled “Demand for Talent: Current & Projected Workforce Trends in the Life Science Industry,” which provides a snapshot of the most current and projected workforce needs within the United States’ life science industry and calls … Continue reading Where Are The Jobs? A New Report Dives Deeper
SOUTH SAN FRANCISCO, Calif. – April 12, 2013 – BayBio today named Henry M. Gunn High School junior Emily Wang and Monta Vista High School junior Natalie Ng as the winners of the 2013 Amgen Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Next up: Wang … Continue reading BayBio Names Henry M. Gunn Junior and Monta Vista High School Junior Amgen Bay Area BioGENEius Finalists
Today at the State Capitol, Assemblyman Marc Levine (D-San Rafael), in partnership with the California Healthcare Institute (CHI), presented a House resolution recognizing Feb. 28, 2013 as Rare Disease Day.
More than one quarter of FDA approvals in 2012 were developed by Bay Area companies, and BayBio will recognize the people and companies that dedicated themselves to bringing these new treatments to patients at its annual Pantheon Awards Ceremony on November 1 in San Francisco.
Oct 1, 2012 SAN FRANCISCO and SAN DIEGO, Calif – October 1, 2012 – BayBio and BIOCOM, the trade associations for the Northern and Southern California life science clusters respectively, today thanked Governor Jerry Brown and Assemblyman Jerry Hill (D-San Mateo) upon the signing of his AB 1277, legislation which addresses facility inspections by state … Continue reading BayBio and BIOCOM Commend Passage of AB 1277 to Reduce Redundant Facilities Inspections
Jun 19, 2012 BOSTON, Mass. – June 19, 2012 – Ten of the brightest young minds in biotech have won the U.S. National BioGENEius Challenge. The winners will now advance to compete with students from Canada and Australia in the International BioGENEius Challenge, which will take place at the 2012 Biotechnology Industry Organization (BIO) International … Continue reading Local Students Win National Science Competition
Mar 8, 2012 SAN FRANCISCO, Calif – March 8, 2012 – More than 1,100 leaders from across California’s life sciences industry will converge on San Francisco, March 8-9, for the two-day conference CALBIO2012: Driven by Patients. The conference focus is to increase patient access to new treatments through partnering and collaborative research. For the first … Continue reading First Statewide Biotech Meeting Focuses on Patient Access, Innovation
Feb 8, 2012 SACRAMENTO, Calif. – Feb. 8, 2012 – After two decades of steady annual job growth, employment in California’s biomedical industry stalled while the state has struggled to recover from financial shortfalls and the industry adapts to a sharp pullback in funding from risk-averse investors in an uncertain regulatory environment, according to the … Continue reading 2012 Report: Biomedical Industry Loses Momentum In California
Jan 10, 2012 SAN FRANCISCO, Calif – Jan 10, 2012 – Access to capital, a burdensome and uncertain regulatory environment and lack of innovation and productivity in research and development are the biggest threats to the biomedical industry’s growth over the next five years, according to biomedical company CEOs surveyed by CHI-California Healthcare Institute, BayBio … Continue reading Survey of Biomedical Industry CEOs Finds Lack of Investment Threatens Future
Oct 5, 2011 SOUTH SAN FRANCISCO, Calif – October 5, 2011 – A recent survey of California’s pioneering industrial biotechnology sector shows that this sector has great potential for job growth in the state. California’s industrial biotechnology industry increased employment by 632 percent in the past five years, according to a survey conducted by BayBio … Continue reading California’s Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
Jul 19, 2011 SOUTH SAN FRANCISCO, Calif – July 19, 2011 – The San Francisco Bay Area is known for its groundbreaking work in science and technology, yet many who call the Bay Area home have little to no opportunity to experience the wonder of science. From October 29 to November 6, 2011, the public … Continue reading BayBio Supports First Annual Bay Area Science Festival: October 29-November 6, 2011
SOUTH SAN FRANCISCO, Calif – July 19, 2011 – The San Francisco Bay Area is known for its groundbreaking work in science and technology, yet many who call the Bay Area home have little to no opportunity to experience the wonder of science. From October 29 to November 6, 2011, the public is invited to … Continue reading BayBio Supports First Annual Bay Area Science Festival: October 29-November 6, 2011
SOUTH SAN FRANCISCO, Calif – June 13, 2011 – BayBio’s 60-second television vignette produced in collaboration with CBS5 on June 11 won an Emmy Award for Commercial – Single Spot or Campaign. Its BayBio’s first Emmy Award. The BayBio Image campaign, also called Behind the Science of Life, was developed to improve the public’s awareness … Continue reading BayBio Campaign Receives Emmy Award
SOUTH SAN FRANCISCO, Calif – April 25, 2011 – Elliott Akama-Garren, a senior at Henry M. Gunn High School, has been named a finalist in the U.S. National BioGENEius Challenge. Ten U.S. National finalists will be selected to join students from Canada and Australia to compete in the International BioGENEius Challenge. The U.S. National and International BioGENEius … Continue reading Henry M. Gunn High School Student a Finalist in Biotechnology Research Competition
BURLINGAME, Calif. – April 21, 2011– All eyes are on how to access the global market place and its resources for biotech research and development at BayBio2011: Powering Global Innovation, the annual conference for Northern California’s life science community. “Life science companies increasingly think outside US borders to develop new treatments, access markets and conduct clinical … Continue reading BayBio Targets International Markets at Annual Conference
BURLINGAME, Calif. – March 22, 2011 – BayBio is proud to present the BayBio2011 Annual Conference Career Fair, an opportunity for leading pharmaceutical and biotech companies to meet face-to-face with experienced job seekers in the Nation’s leading innovation hub. BioSpace Career Fair at BayBio2011 Wednesday, April 20, 2011 1pm to 6pm Hyatt Regency San Francisco Airport … Continue reading BayBio Hosts Career Fair with BioSpace and BHRN at BayBio2011 Annual Conference
SOUTH SAN FRANCISCO, Calif. – February 24, 2011 – Taking a queue from President Barrack Obama’s State of the Union Address and StartUp America, BayBio introduced two new programs to assist entrepreneurs and startups. “The Federal bureaucracy can raise awareness and create fiscal incentives to promote innovation, but they are looking to industry and local organizations to … Continue reading New BayBio Programs Deliver Offerings to Bay Area Entrepreneurs
Eighty percent of biomedical company CEOs in California report that their companies have been courted by other countries, state governments or regional economic development associations in the past year, according to survey findings included in the 2011 California Biomedical Industry Report, published today by the California Healthcare Institute, BayBio and PwC. Yet the survey found … Continue reading California’s Biomedical Industry is Poised
SOUTH SAN FRANCISCO, Calif. – January 1, 2011—OncoMed Pharmaceuticals CEO Paul Hastings will serve another term as Chairman of the Board of BayBio, Northern California’s life sciences association. In addition, the trade association also announced the appointment of Stanford University’s Michael Alvarez as chair of the BayBio Institute. Vice Chairs to the two boards were … Continue reading BayBio Board Brings Stability to the Life Sciences Community
SOUTH SAN FRANCISCO, Calif. – November 5, 2010 – Two new treatments made available to patients this year were recognized among the 10 recipients of DiNA‚Ñ¢ Awards at the 2010 Pantheon Ceremony on November 4. Each year BayBio presents the DiNA Awards to recognize achievement and honor excellence in the life sciences industry in Northern … Continue reading Pantheon Awardees Represent Local Influence on International Scene
SOUTH SAN FRANCISCO, Calif. – October 15, 2010 – New functions and features assist BayBio visitors in discovering biotechnology related content at the Northern California life science association’s new websites www.baybio.org and www.baybioinstitute.org. “We began with a basic premise: simplify the experience for our visitors,” said BayBio’s Gail Maderis, president and CEO. “Our intention is to make it easier to … Continue reading BayBio Adds New Functions to Re-Designed Websites
SOUTH SAN FRANCISCO, Calif. – September 21, 2010 – A recent survey of California’s new industrial biotechnology sector shows that this state is once again the hub of innovation for an emerging industry. California’s industrial biotechnology industry is creating new jobs for skilled workers and promises to benefit the world through new and sustainable fuel … Continue reading California’s Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation